AVITA Medical, Inc. (RCEL) Cash from Financing Activities (2019 - 2025)

AVITA Medical (RCEL) has reported Cash from Financing Activities for 7 consecutive years, with $248000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities fell 75.71% year-over-year to $248000.0; the trailing twelve-month figure through Dec 2025 stood at $14.9 million (up 325.77% YoY), and the FY2025 full-year result was $14.9 million, up 325.77% from the prior year.
• Cash from Financing Activities fell to $248000.0 in Q4 2025 per RCEL's latest filing, from $13.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $64.1 million in Q3 2021 and bottomed at -$64.1 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged $3.5 million across 5 years, with a median of $600000.0 in 2023.
• The widest YoY moves for Cash from Financing Activities: up 1601625.0% in 2021, down 1280120.0% in 2021.
• Over 5 years, Cash from Financing Activities stood at -$64.0 million in 2021, then dropped by 0.08% to -$64.1 million in 2022, then surged by 161.55% to $39.4 million in 2023, then plunged by 97.41% to $1.0 million in 2024, then tumbled by 75.71% to $248000.0 in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $248000.0, $13.8 million, and $559000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.